Sunday 8 November 2026 Export OGN’s income statement to Excel — free account

Organon & Co.

OGN

Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.

Revenue: −1.75%
EPS: +1.64%
Free cash flow: +118.8%
Total debt: −3.10%

Quarter to September 2026, against a year earlier

13.87 0.08 +0.58%

Follow OGN

Alert me

Market cap: $3.6B
P/E: 17.3×
Fwd P/E: 6.2×
Dividend yield: 0.58%
F-score: 5/9
ROIC: 6.26%
Net debt / EBITDA: 5.6×
Dividend safety: 45/100

Overview

Organon & Co. (OGN) Price to free cash flow

Alert me on Price to free cash flow

As of 6 November 2026, Organon & Co. (OGN) trades at a price to free cash flow of 6.3×. Over the past ten years it has ranged from 2.6× (October 2025) to 33.3× (July 2022); the current reading is higher than 48% of that period. That is below the Drug Manufacturers General industry median of 21.7× and below the Healthcare sector median of 20.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/OGN/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Organon &amp; Co. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/OGN/metrics/price-to-free-cash-flow">Organon &amp; Co. (OGN) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	4.5×	(22.49%)
FY2024	5.8×	(30.21%)
FY2023	8.3×	(36.67%)
FY2022	13.1×	234.78%
FY2021	3.9×	15.15%
FY2020	3.4×	0.00%
FY2019	3.4×	0.00%
FY2018	3.4×	0.00%
FY2017	3.4×	—

Period	Price to free cash flow	Change
Sep 2026	6.3×	(17.92%)
Jun 2026	7.7×	175.16%
Mar 2026	2.8×	(37.88%)
Dec 2025	4.5×	0.76%
23 more quarters	Free account

Against its own ten years

Low 2.6× High 33.3×

Ten-year median 6.5×

Current reading's percentile 48

Company	Price to free cash flow
OGN Organon & Co.	6.3×
AMRN Amarin Corporation PLC compare	6.5×
SNY Sanofi compare	6.7×
GRFS Grifols, S.A. compare	7.6×
GSK GSK PLC Sponsored ADR compare	11.4×
BMY Bristol Myers Squibb Company compare	13.7×
PFE Pfizer Inc. compare	15.2×
BIIB Biogen Inc. compare	21.7×
NVO Novo Nordisk A/S compare	25.8×
Drug Manufacturers General industry median	21.7×
Healthcare sector median	20.5×
Market median	14.0×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Organon & Co. (OGN) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on OGN

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on OGN

Stockrow Weekly